Navigation Links
Pharmaceutical Industry Service Company Awarded The UK's Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
Date:4/20/2012

LONDON, April 21, 2012 /PRNewswire/ --

Medaxial, the healthcare value communication specialist, today announces that it has won a Queen's Award for Enterprise in recognition of its international trade achievements.

The Queen's Awards for Enterprise are the UK's most prestigious business accolade, bestowed by Her Majesty Queen Elizabeth II on a select number of companies who have achieved outstanding results in international trade, innovation or sustainable development.  The awards are announced each year on April 21, The Queen's birthday.

Medaxial provides value communication solutions to many of the best-known names in the pharmaceutical, medical devices and diagnostics industries, and has been particularly successful in developing a client base in Europe and the USA.  The company's portfolio of services includes landscape and competitor assessment, clinical trial optimisation advice, pricing research, revenue forecasting, value message development and testing, strategic market access consultancy, health economic modelling, value dossier development, value communication toolkits and a wide range of tactical sales tools.  

Reacting to the news, one of the founding directors of Medaxial, John Fanshawe, said, "We have always believed that Medaxial's unique value communication perspective helps our clients to prosper in what are very difficult market conditions.  With continued pressure on healthcare budgets and the ever-increasing cost of bringing products to market, most pharmaceutical, biotechnology and medical devices companies now recognise the critical importance of successfully communicating the value of their products to the stakeholders who are expected to pay for them.  We have remained faithful to our belief in the central importance of value communication, and have built a reputation within the global healthcare industry for combining a rigorous approach to science and health economics with world-class communication expertise."

Paul Mcloughlin, also a founding director, added, "As a British company competing against some major overseas players, we operate in a tough and unforgiving marketplace, so we are absolutely delighted to receive this recognition.  Our growth over recent years is a testament to our understanding of the healthcare industry and the issues it faces, our insight into the decision-making processes in global healthcare systems, and the innovative value communication solutions that we provide."

About Medaxial

Medaxial is a specialist value communication consultancy with more than 15 years' experience of serving the global healthcare industry.  The services the company offers are based on two core beliefs: First, that no activity is more important to innovative healthcare companies than the communication of product value; and second, that value communication is inextricably linked to pricing, reimbursement, stakeholder research, health economic research and clinical evidence generation.

Medaxial is the only consultancy specialising in value communication that offers health economic, pricing and market access services. The company's value communication perspective ensures that all activities are focused on the central task of communicating product value in order to optimise commercial success.

The result is a highly-focused portfolio of services that helps clients demonstrate the value of innovative medicines, medical devices and diagnostic technologies, based on robust scientific evidence and high-quality market research.  

Medaxial is headquartered in London, England, and has an office in New York City serving the North American marketplace.  

About the Queen's Awards

Click this link for more information about The Queen's Awards



'/>"/>
SOURCE Medaxial
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition ... to their offering. ... The global oxygen therapy devices market to grow at a ... report, Global Oxygen Therapy Devices Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:3/23/2017)... 2017 A research report by Mordor ... to reach USD 7.2 billion by the end of 2021 ... a procedure in which a sample is preserved prior to ... procedures since the methods are often allowing repeated testing. The ... most shared procedures in the lab. In many life science ...
(Date:3/23/2017)... -- Newborns are highly vulnerable to infections and ... young immune systems typically mount weak antibody responses. ... strong vaccine responses in newborn animals, including monkeys ... — by adding compounds known as adjuvants that ... they also describe improved adjuvant formulations that could ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National Council on ... The NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at ... in the U.S. It argues that this higher bar should be set by states, ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... their communities, 16 more public health departments have been awarded national accreditation through ... 4.5 million people into the expanding network of communities across the nation whose ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... City Convention Center at 10 North Broadway Avenue, will be an educational and ... relevant, practical instruction in the management of chronic pain. , Oklahoma is in ...
Breaking Medicine News(10 mins):